Successful long-term management with toceranib phosphate of a recurrent muzzle mast cell tumour in a dog

https://doi.org/10.17221/78/2019-VETMEDCitation:Kim H., Kim J. (2020): Successful long-term management with toceranib phosphate of a recurrent muzzle mast cell tumour in a dog. Veterinarni Medicina, 65: 227-232.
download PDF

A 10-year-old spayed female Yorkshire terrier with a muzzle mass was presented. The ulcerated mass was surgically resected, but recurred and grew rapidly over the subsequent 7 months. The submandibular lymph nodes were remarkably enlarged (right: 9.5 × 7.8 cm; left, 4.7 × 4.0 cm). The cytological analysis of the mass and lymph nodes revealed a high-risk mast cell tumour characterised by high mitotic figures (> 5/oil immersion field), nuclear pleomorphism, multi-nucleation, karyomegaly, and anisokaryosis. A polymerase chain reaction analysis targeting the c-kit domain revealed an exon 8 mutation. The resection of the mass was not considered optional because of the location. Oral toceranib (3.25 mg/kg, every other day) and prednisolone (1.0 mg/kg to 0.5 mg/kg, once a day) were administered, and the mass disappeared within 1 month. Subsequently, the toceranib therapy was stopped for 4 months due to neutropenia (0.7 × 109/l). However, the mass recurred and the toceranib was resumed at the original dose, without affecting the neutropenia. No recurrence has been observed at the 16 months’ follow up. Despite the persistent neutropenia, no clinical symptoms have presented. This is another report of the successful treatment of a recurrent muzzle MCT with toceranib in a dog.

References:
Al Enazi MM, Kadry R, Mitwali H. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma. J Am Acad Dermatol. 2009 Nov;61(5):905-6. https://doi.org/10.1016/j.jaad.2008.12.030
 
Alexeev V, Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol. 2006 May;126(5):1102-10. https://doi.org/10.1038/sj.jid.5700125
 
Bernabe LF, Portela R, Nguyen S, Kisseberth WC, Pennell M, Yancey MF, London CA. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Vet Res. 2013 Sep 30;9:190. https://doi.org/10.1186/1746-6148-9-190
 
Blackwood L, Murphy S, Buracco P, De Vos JP, De Fornel-Thibaud P, Hirschberger J, Kessler M, Pastor J, Ponce F, Savary-Bataille K, Argyle DJ. European consensus document on mast cell tumours in dogs and cats. Vet Comp Oncol. 2012 Sep;10(3):e1-e29. https://doi.org/10.1111/j.1476-5829.2012.00341.x
 
Carlsten KS, London CA, Haney S, Burnett R, Avery AC, Thamm DH. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors. J Vet Intern Med. 2012 Jan-Feb;26(1):135-41. https://doi.org/10.1111/j.1939-1676.2011.00851.x
 
Cavalcanti JVJ, Hasbach A, Barnes K, Dange RB, Patterson J, Saavedra PV. Skin depigmentation associated with toceranib phosphate in a dog. Vet Dermatol. 2017 Aug;28(4):400-e95. https://doi.org/10.1111/vde.12422
 
Flesner BK, Fletcher JM, Smithee T, Boudreaux B. Long-term survival and glycemic control with toceranib phosphate and prednisone for a metastatic canine insulinoma. J Am Anim Hosp Assoc. 2019 Jan/Feb;55(1):e55105. https://doi.org/10.5326/JAAHA-MS-6751
 
Giacchero D, Ramacciotti C, Arnault JP, Brassard M, Baudin E, Maksimovic L, Mateus C, Tomasic G, Wechsler J, Schlumberger M, Robert C. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol. 2012 Dec;148(12):1418-20. https://doi.org/10.1001/2013.jamadermatol.192
 
Halsey CHC, Thamm DH, Weishaar KM, Burton JH, Charles JB, Gustafson DL, Avery AC, Ehrhart EJ. Expression of phosphorylated KIT in canine mast cell tumor. Vet Pathol. 2017 May;54(3):387-94. https://doi.org/10.1177/0300985816688943
 
Hillman LA, Garrett LD, de Lorimier LP, Charney SC, Borst LB, Fan TM. Biological behavior of oral and perioral mast cell tumors in dogs: 44 cases (1996−2006). J Am Vet Med Assoc. 2010 Oct 15;237(8):936-42. https://doi.org/10.2460/javma.237.8.936
 
Kim JH, Kim HJ, Kim DH, Yim JH, Lee SJ, Park KH, Yoon HY. Successful response to imatinib in two dogs with inoperable grade III infiltrating mast cell tumours: A case report. Vet Med-Czech. 2016 Aug;61(8):467-73.  https://doi.org/10.17221/87/2016-VETMED
 
Kobayashi M, Sugisaki O, Ishii N, Yamada O, Ito K, Kuroki S, Sasaki Y, Ono K, Washizu T, Bonkobara M. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy. Vet J. 2012 Jul;193(1):264-7. https://doi.org/10.1016/j.tvjl.2011.10.027
 
London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res. 2009 Jun 1;15(11):3856-65. https://doi.org/10.1158/1078-0432.CCR-08-1860
 
Marconato L, Bettini G, Giacoboni C, Romanelli G, Cesari A, Zatelli A, Zini E. Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement. J Vet Intern Med. 2008 Jul-Aug;22(4):1001-7. https://doi.org/10.1111/j.1939-1676.2008.0128.x
 
Moirano SJ, Lima SF, Hume KR, Brodsky EM. Association of prognostic features and treatment on survival time of dogs with systemic mastocytosis: A retrospective analysis of 40 dogs. Vet Comp Oncol. 2018 Mar;16(1):E194-E201. https://doi.org/10.1111/vco.12373
 
Scarpa F, Sabattini S, Bettini G. Cytological grading of canine cutaneous mast cell tumours. Vet Comp Oncol. 2016 Sep;14(3):245-51. https://doi.org/10.1111/vco.12090
 
Takeuchi Y, Fujino Y, Watanabe M, Takahashi M, Nakagawa T, Takeuchi A, Bonkobara M, Kobayashi T, Ohno K, Uchida K, Asano K, Nishimura R, Nakayama H, Sugano S, Ohashi Y, Tsujimoto H. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: A retrospective cohort study. Vet J. 2013 Jun;196(3):492-8. https://doi.org/10.1016/j.tvjl.2012.11.018
 
Thamm DH, Weishaar KM, Charles JB, Ehrhart EJ 3rd. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine. Vet Comp Oncol. 2019 Jul;18(2):169-75. https://doi.org/10.1111/vco.12525
 
Thompson JJ, Morrison JA, Pearl DL, Boston SE, Wood GA, Foster RA, Coomber BL. Receptor tyrosine kinase expression profiles in canine cutaneous and subcutaneous mast cell tumors. Vet Pathol. 2016 May;53(3):545-58. https://doi.org/10.1177/0300985815610388
 
VCOG. Veterinary cooperative oncology group – Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2016 Dec;14(4):417-46. https://doi.org/10.1111/vco.283
 
Welle MM, Bley CR, Howard J, Rufenacht S. Canine mast cell tumours: A review of the pathogenesis, clinical features, pathology and treatment. Vet Dermatol. 2008 Dec;19(6):321-39. https://doi.org/10.1111/j.1365-3164.2008.00694.x
 
download PDF

© 2022 Czech Academy of Agricultural Sciences | Prohlášení o přístupnosti